{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:58:04Z","timestamp":1790384284064,"version":"4.1.0"},"reference-count":71,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2016,1,12]]},"abstract":"<jats:p>Alzheimer\u2019s disease (AD), the prevalent dementia in the elderly, involves many related and interdependent pathologies that manifests simultaneously, eventually leading to cognitive impairment and death. No treatment is currently available; however, an agent addressing several key pathologies simultaneously has a better therapeutic potential. Human serum albumin (HSA) is a highly versatile protein, harboring multifunctional properties that are relevant to key pathologies underlying AD. This study provides insight into the mechanism for HSA\u2019s therapeutic effect. In vivo, a myriad of beneficial effects were observed by pumps infusing HSA intracerebroventricularly, for the first time in an AD 3xTg mice model. A significant effect on amyloid-\u03b2 (A\u03b2) pathology was observed. A\u03b21-42, soluble oligomers, and total plaque area were reduced. Neuroblastoma SHSY5Y cell line confirmed that the reduction in A\u03b21-42 toxicity was due to direct binding rather than other properties of HSA. Total and hyperphosphorylated tau were reduced along with an increase in tubulin, suggesting increased microtubule stability. HSA treatment also reduced brain inflammation, affecting both astrocytes and microglia markers. Finally, evidence for blood-brain barrier and myelin integrity repair was observed. These multidimensional beneficial effects of intracranial administrated HSA, together or individually, contributed to an improvement in cognitive tests, suggesting a non-immune or A\u03b2 efflux dependent means for treating AD.<\/jats:p>","DOI":"10.3233\/jad-150694","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T10:10:17Z","timestamp":1452247817000},"page":"175-188","source":"Crossref","is-referenced-by-count":46,"title":["Multifunctional Effect of Human Serum Albumin Reduces Alzheimer\u2019s Disease Related Pathologies in the 3xTg Mouse Model"],"prefix":"10.1177","volume":"50","author":[{"given":"Assaf","family":"Ezra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Rabinovich-Nikitin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Rabinovich-Toidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beka","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-150694_ref1","first-page":"739","article-title":"Prediction of survival in Alzheimer\u2019s disease\u2013the LASER-AD longitudinal study","volume":"24","author":"Paradise","year":"2009","journal-title":"Int J GeriatrPsychiatry"},{"key":"10.3233\/JAD-150694_ref2","first-page":"5","article-title":"Neuropathological hallmarks of Alzheimer\u2019s disease","volume":"9","author":"Cvetkovic-Dozic","year":"2001","journal-title":"Arch Oncol"},{"key":"10.3233\/JAD-150694_ref3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-150694_ref4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1155\/S1110724302203010","article-title":"Alzheimer disease and oxidative stress","volume":"2","author":"Perry","year":"2002","journal-title":"J Biomed Biotechnol"},{"key":"10.3233\/JAD-150694_ref5","doi-asserted-by":"crossref","first-page":"9170","DOI":"10.1523\/JNEUROSCI.19-21-09170.1999","article-title":"The Alzheimer\u2019s disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures","volume":"19","author":"White","year":"1999","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-150694_ref6","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1126\/science.271.5254.1406","article-title":"The amyloid precursor protein of Alzheimer\u2019s disease in the reduction of copper(II) to copper(I)","volume":"271","author":"Multhaup","year":"1996","journal-title":"Science"},{"key":"10.3233\/JAD-150694_ref7","doi-asserted-by":"crossref","first-page":"184042","DOI":"10.1155\/2012\/184042","article-title":"Dyslipidemia and blood-brain barrier integrity in Alzheimer\u2019s disease","volume":"2012","author":"Bowman","year":"2012","journal-title":"Curr Gerontol Geriatr Res"},{"key":"10.3233\/JAD-150694_ref8","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.20720","article-title":"Albumin: Biochemical properties and therapeutic potential","volume":"41","author":"Quinlan","year":"2005","journal-title":"Hepatology"},{"key":"10.3233\/JAD-150694_ref9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jmb.2008.06.016","article-title":"Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha","volume":"381","author":"Zunszain","year":"2008","journal-title":"J Mol Biol"},{"key":"10.3233\/JAD-150694_ref10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/mvre.1998.2126","article-title":"Inhibition of microvascular endothelial apoptosis in tissue explants by serum albumin","volume":"57","author":"Zoellner","year":"1999","journal-title":"Microvasc Res"},{"key":"10.3233\/JAD-150694_ref11","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00001756-200211150-00032","article-title":"Albumin protects human red blood cells against Abeta25-35-induced lysis more effectively than ApoE","volume":"13","author":"Galeazzi","year":"2002","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-150694_ref12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/BF01412002","article-title":"The effect of inttricular albumin in experimental brain oedema","volume":"139","author":"Onal","year":"1997","journal-title":"Acta Neurochir (Wien)"},{"key":"10.3233\/JAD-150694_ref13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.STR.32.2.553","article-title":"Human albumin therapy of acute ischemic stroke: Marked neuroprotective efficacy at moderate doses and with a broad therapeutic window","volume":"32","author":"Belayev","year":"2001","journal-title":"Stroke"},{"key":"10.3233\/JAD-150694_ref14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1471-4159.2002.00843.x","article-title":"Albumin promotes neuronal survival by increasing the synthesis and release of glutamate","volume":"81","author":"Tabernero","year":"2002","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-150694_ref15","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.STR.0000110790.05859.DA","article-title":"Human serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death","volume":"35","author":"Gum","year":"2004","journal-title":"Stroke"},{"key":"10.3233\/JAD-150694_ref16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2125.1990.tb03620.x","article-title":"The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein","volume":"29","author":"Veering","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.3233\/JAD-150694_ref17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/156720510790274392","article-title":"Serum albumin concentration and cognitive impairment","volume":"7","author":"Llewellyn","year":"2010","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-150694_ref18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1749-6632.1982.tb26848.x","article-title":"Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT)","volume":"396","author":"Wisniewski","year":"1982","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-150694_ref19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1006\/bbrc.2000.2222","article-title":"Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma","volume":"268","author":"Kuo","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/JAD-150694_ref20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bpj.2010.11.037","article-title":"Stoichiometry and affinity of the human serum albumin-Alzheimer\u2019s A\u03b2 peptide interactions","volume":"100","author":"Milojevic","year":"2011","journal-title":"Biophys J"},{"key":"10.3233\/JAD-150694_ref21","doi-asserted-by":"crossref","first-page":"32916","DOI":"10.1074\/jbc.271.51.32916","article-title":"Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma","volume":"271","author":"Biere","year":"1996","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-150694_ref22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/ggi.12147","article-title":"Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer\u2019s disease","volume":"14","author":"Yamamoto","year":"2014","journal-title":"Geriatr Gerontol Int"},{"key":"10.3233\/JAD-150694_ref23","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.bpj.2009.08.028","article-title":"Human serum albumin inhibits Abeta fibrillization through a \u201cmonomer-competitor\u201d mechanism","volume":"97","author":"Milojevic","year":"2009","journal-title":"Biophys J"},{"key":"10.3233\/JAD-150694_ref24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: Intracellular A(and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"key":"10.3233\/JAD-150694_ref25","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1523\/JNEUROSCI.5633-07.2008","article-title":"Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits","volume":"28","author":"Belinson","year":"2008","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-150694_ref26","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1074\/jbc.M112.409250","article-title":"Inhibition of glycogen synthase kinase-3 ameliorates \u03b2-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: In vivo and in vitro studies","volume":"288","author":"Avrahami","year":"2013","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-150694_ref27","doi-asserted-by":"crossref","first-page":"6755","DOI":"10.1523\/JNEUROSCI.1247-05.2005","article-title":"Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice","volume":"25","author":"Saura","year":"2005","journal-title":"J Neurosci"},{"issue":"Suppl","key":"10.3233\/JAD-150694_ref28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1471-4159.2011.07478.x","article-title":"Soluble A\u03b2 oligomer production and toxicity","volume":"120","author":"Larson","year":"2012","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-150694_ref29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A beta oligomers - a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-150694_ref30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1754-1611-3-5","article-title":"Soluble aggregates of the amyloid-beta peptide are trapped by serum albumin to enhance amyloid-beta activation of endothelial cells","volume":"3","author":"Reyes Barcelo","year":"2009","journal-title":"J Biol Eng"},{"key":"10.3233\/JAD-150694_ref31","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bpj.2013.08.025","article-title":"Mapping the Interactions between the Alzheimer\u2019s A\u03b2-peptide and human serum albumin beyond domain resolution","volume":"105","author":"Algamal","year":"2013","journal-title":"Biophys J"},{"key":"10.3233\/JAD-150694_ref32","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1474-9726.2008.00434.x","article-title":"Selective induction of calcineurin activity and signaling by oligomeric amyloid beta","volume":"7","author":"Reese","year":"2008","journal-title":"Aging Cell"},{"key":"10.3233\/JAD-150694_ref33","doi-asserted-by":"crossref","first-page":"17294","DOI":"10.1074\/jbc.M500997200","article-title":"Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers","volume":"280","author":"Demuro","year":"2005","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-150694_ref34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2012.07.004","article-title":"Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer\u2019s disease expressing mutated APP, PS1, and Mapt (3xTg-AD)","volume":"234","author":"Filali","year":"2012","journal-title":"Behav Brain Res"},{"key":"10.3233\/JAD-150694_ref35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbr.2015.04.012","article-title":"Early detection of cognitive deficits in the 3xTg-AD mouse model of Alzheimer\u2019s disease","volume":"289","author":"Stover","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.3233\/JAD-150694_ref36","doi-asserted-by":"crossref","first-page":"15990","DOI":"10.1074\/jbc.274.23.15990","article-title":"Endogenous proteins controlling amyloid \u03b2-peptide polymerization","volume":"274","author":"Bohrmann","year":"1999","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-150694_ref37","doi-asserted-by":"crossref","first-page":"28163","DOI":"10.1074\/jbc.C112.360800","article-title":"Human serum albumin can regulate amyloid-\u03b2 peptide fiber growth in the brain interstitium: Implications for Alzheimer disease","volume":"287","author":"Stanyon","year":"2012","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-150694_ref38","doi-asserted-by":"crossref","first-page":"e46650","DOI":"10.1371\/journal.pone.0046650","article-title":"Beneficial effect of antibodies against \u03b2- secretase cleavage site of APP on Alzheimer\u2019s-like pathology in triple-transgenic mice","volume":"7","author":"Rabinovich-Nikitin","year":"2012","journal-title":"PLoS One"},{"key":"10.3233\/JAD-150694_ref39","doi-asserted-by":"crossref","unstructured":"Oh K-J , Perez SE , Lagalwar S , Vana L , Binder L , Mufson EJ (2010) Staging of Alzheimer\u2019s pathology in triple transgenic mice: A light and electron microscopic analysis. Int J Alzheimers Dis 2010, pii: 780102.","DOI":"10.4061\/2010\/780102"},{"key":"10.3233\/JAD-150694_ref40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jnr.490390607","article-title":"Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404","volume":"39","author":"Otvos","year":"1994","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-150694_ref41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/glia.440020605","article-title":"Patterns of gliosis in Alzheimer\u2019s disease and aging cerebrum","volume":"2","author":"Beach","year":"1989","journal-title":"Glia"},{"key":"10.3233\/JAD-150694_ref42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1742-2094-9-195","article-title":"Astrocyte elevated gene-1 regulates astrocyte responses to neural injury:Implications for reactive astrogliosis and neurodegeneration","volume":"9","author":"Vartak-Sharma","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JAD-150694_ref43","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.neurobiolaging.2012.10.007","article-title":"Age-related changes in neuroactive steroid levels in 3xTg-AD mice","volume":"34","author":"Caruso","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-150694_ref44","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1096\/fj.05-3956com","article-title":"Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease","volume":"20","author":"Dickstein","year":"2006","journal-title":"FASEB J"},{"key":"10.3233\/JAD-150694_ref45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000334916","article-title":"Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy","volume":"10","author":"Carrano","year":"2012","journal-title":"Neurodegener Dis"},{"key":"10.3233\/JAD-150694_ref46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/glia.20734","article-title":"Triple-transgenic Alzheimer\u2019s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology","volume":"57","author":"Desai","year":"2009","journal-title":"Glia"},{"key":"10.3233\/JAD-150694_ref47","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/glia.22432","article-title":"Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men","volume":"61","author":"Behrendt","year":"2013","journal-title":"Glia"},{"key":"10.3233\/JAD-150694_ref48","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2353\/ajpath.2010.100087","article-title":"Early oligodendrocyte\/myelin pathology in Alzheimer\u2019s disease mice constitutes a novel therapeutic target","volume":"177","author":"Desai","year":"2010","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-150694_ref49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/35086072","article-title":"Alzheimer\u2019s disease and Abeta toxicity: From top to bottom","volume":"2","author":"Small","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-150694_ref50","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jnr.10328","article-title":"Paradigm shifts in Alzheimer\u2019s disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies","volume":"69","author":"Kirkitadze","year":"2002","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-150694_ref51","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1111\/j.1742-4658.2011.08228.x","article-title":"Membrane and surface interactions of Alzheimer\u2019s A\u03b2 peptide\u2013insights into the mechanism of cytotoxicity","volume":"278","author":"Williams","year":"2011","journal-title":"FEBS J"},{"key":"10.3233\/JAD-150694_ref52","doi-asserted-by":"crossref","unstructured":"Ferreira ST, Vieira MNN, De Felice. FG Soluble protein oligomers as emerging toxins in Alzheimer\u2019s and other amyloid diseases. IUBMB Life 59, 332\u2013345.","DOI":"10.1080\/15216540701283882"},{"key":"10.3233\/JAD-150694_ref53","doi-asserted-by":"crossref","first-page":"33298","DOI":"10.1074\/jbc.M305207200","article-title":"Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies","volume":"278","author":"Makrides","year":"2003","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-150694_ref54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-4-13","article-title":"The role of tau in neurodegeneration","volume":"4","author":"Gendron","year":"2009","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-150694_ref55","doi-asserted-by":"crossref","first-page":"17345","DOI":"10.1523\/JNEUROSCI.0172-12.2012","article-title":"Soluble A\u03b2 promotes wild-type tau pathology in vivo","volume":"32","author":"Chabrier","year":"2012","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-150694_ref56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/glia.1072","article-title":"Inflammatory repertoire of Alzheimer\u2019s disease and nondemented elderly microglia in vitro","volume":"35","author":"Lue","year":"2001","journal-title":"Glia"},{"key":"10.3233\/JAD-150694_ref57","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/jcbfm.2013.135","article-title":"Blood-brain barrier dysfunction as a cause and consequence of Alzheimer\u2019s disease","volume":"33","author":"Erickson","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JAD-150694_ref58","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1474-4422(04)00683-0","article-title":"Is Alzheimer\u2019s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics","volume":"3","author":"De La Torre","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-150694_ref59","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1523\/JNEUROSCI.0006-15.2015","article-title":"Amyloid (oligomers disrupt blood \u2013 CSF barrier integrity by activating matrix metalloproteinases","volume":"35","author":"Brkic","year":"2015","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-150694_ref60","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.neurobiolaging.2013.02.010","article-title":"Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model","volume":"34","author":"Takeda","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-150694_ref61","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.neurobiolaging.2010.05.007","article-title":"Amyloid \u03b21-42 oligomer inhibits myelin sheet formation in vitro","volume":"33","author":"Horiuchi","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.3233\/JAD-150694_ref62","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1021\/bi4001936","article-title":"Fine mapping of the amyloid \u03b2-protein binding site on myelin basic protein","volume":"52","author":"Kotarba","year":"2013","journal-title":"Biochemistry"},{"key":"10.3233\/JAD-150694_ref63","doi-asserted-by":"crossref","first-page":"35590","DOI":"10.1074\/jbc.M110.169599","article-title":"N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly","volume":"285","author":"Liao","year":"2010","journal-title":"J. Biol. Chem"},{"key":"10.3233\/JAD-150694_ref64","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/glia.22367","article-title":"Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions","volume":"60","author":"Clarner","year":"2012","journal-title":"Glia"},{"key":"10.3233\/JAD-150694_ref65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/2051-5960-1-43","article-title":"Myelin alters the inflammatory phenotype of macrophages by activating PPARs","volume":"1","author":"Bogie","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-150694_ref66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neulet.2008.10.108","article-title":"Albumin attenuates DNA damage in primary-cultured neurons","volume":"450","author":"Baltan\u00e1s","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-150694_ref67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1358\/dnp.2009.22.6.1395256","article-title":"Amyloid-targeted therapeutics in Alzheimer\u2019s disease: Use of human albumin in plasma exchange as a novel approach for Abeta mobilization","volume":"22","author":"Boada","year":"2009","journal-title":"Drug News Perspect"},{"key":"10.3233\/JAD-150694_ref68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2045-8118-8-21","article-title":"Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent","volume":"8","author":"Pascale","year":"2011","journal-title":"Fluids Barriers CNS"},{"key":"10.3233\/JAD-150694_ref69","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI10498","article-title":"Clearance of Alzheimer\u2019s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier","volume":"106","author":"Shibata","year":"2000","journal-title":"J Clin Invest"},{"key":"10.3233\/JAD-150694_ref70","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS \u03b2-amyloid in Alzheimer\u2019s disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"10.3233\/JAD-150694_ref71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1326-8-36","article-title":"Immunotherapy for Alzheimer\u2019s disease: Hoops and hurdles","volume":"8","author":"Lemere","year":"2013","journal-title":"Mol Neurodegener"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-150694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:01:54Z","timestamp":1777370514000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-150694"}},"subtitle":[],"editor":[{"given":"Debomoy","family":"Lahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,12]]},"references-count":71,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-150694","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,12]]}}}